At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, and plenty more. (Here’s a link to last year’s roundup.)
Existing platforms are being expanded upon to cater to more patients, while new platforms like implants and all-in-one systems are being designed to manage diabetes in new and innovative ways.
BTIG analysts Marie Thibault, Sam Eiber and Alexandra Pang say the space is gearing up for some serious movement down the line.
“Diabetes tech continues to move quickly and is being helped by favorable coverage, label expansions, and growing awareness,” the analysts wrote. “We expect market growth rates for both CGMs and pumps to remain well above most of medtech, but given timelines for future product launches, we see this as a development year, with potential for market shifts in 2026 or beyond.”
Here are the standout stories from this year’s American Diabetes Association Scientific Sessions in Chicago:
Abbott Diabetes head talks dual sensor, Medtronic partnership
One of the most exciting new developments has been the company’s dual glucose-ketone sensor. Built on the form factor of the latest-generation FreeStyle Libre 3 Plus continuous glucose monitor, the dual sensor will also pair with automated insulin delivery systems. Abbott already has several planned integrations for when its sensor hits the market — potentially next year, the analysts say. It agreed to integration deals with Sequel Med Tech, Tandem Diabetes Care, Beta Bionics, then Ypsomed and CamDiab.
Elsewhere, Scoggins touched on the company’s global partnership pairing Abbott CGMs with Medtronic insulin delivery systems. Medtronic announced the submission of an interoperable pump with the Abbott sensor technology to the FDA in April. Scoggins said the partnership may have caught many off-guard, but will nevertheless provide new benefits to the diabetes community.
He also explained some of the latest developments at Abbott, like the launch of a universal FreeStyle Libre app in the U.S. and a new partnership to integrate data from Libre systems directly into Epic EHR.
Read Scoggins’ breakdown of the company’s exciting dual sensor.
Read more about the Medtronic partnership and other tech updates at Abbott.
Medtronic has positive MiniMed 780G data, next-gen tech updates
The company, which Medtronic plans to separate its Diabetes unit into a separate company called MiniMed within the next 18 months, highlighted improved glycemic outcomes for those with type 2 diabetes and in young children. Medtronic’s system remains investigational for type 2 diabetes while the company awaits potential FDA approval. The company hopes to work with global regulators to expand access to its technology for the type 2 population, plus a lower age indication for type 1.
Meanwhile, the unit’s pipeline continues to expand. It expects to submit a new automated insulin delivery system, the MiniMed Flex (8 series) pump, to the FDA by the end of the fiscal year. (Medtronic’s fiscal year ends in April, meaning the submission could come by spring 2026.) Analysts also say they received a look at the company’s in-development MiniMed Fit patch pump as it looks to enter that market, too.
Read about the data shared by Medtronic at ADA.
Read about the next-generation technologies Medtronic has under development.
Tandem leader talks developments as pump highlights benefits in pregnant women
Mainly, the rollout of Control-IQ+, the next generation of the company’s advanced hybrid closed-loop insulin delivery algorithm, reflects advancements in automated insulin delivery at Tandem. Control-IQ+ has compatibility with both the company’s pump offerings, the t:slim X2 and Mobi pumps. The company said the algorithm is now available for people with type 1 diabetes aged two years and older, as well as adults with type 2 diabetes.
Tandem also has new CGM integrations to tout, updated infusion sets and potentially even more differentiated pump tech on the way.
Also at ADA, a study evaluating the use of t:slim X2 in pregnant women with type 1 diabetes highlighted improved glucose control. The study showed that pregnant women with type 1 diabetes stayed in the target glucose range for pregnancy more with the Tandem t:slim X2 with Control-IQ technology compared to standard insulin delivery with injections or open-loop, non-automated insulin pump therapy with continuous glucose monitoring (CGM).
Read more from Mar on Tandem’s latest milestones.
Read more about the study of AID in pregnant women.
Dexcom pushes for type 2 diabetes awareness, touts AI enhancements
Findings provide insights into perceptions around diabetes technology from more than 400 healthcare professionals and people with type 2 diabetes across the U.S.
Speaking to Drug Delivery Business News at ADA, Dexcom President and COO Jake Leach outlined the push toward type 2 and explained how the company continues to drive interest in its sensor platforms, especially with new AI-based upgrades.
Included in those AI-based upgrades is a new food logging feature. The technology is proprietary to Dexcom’s app, enabled through Google’s Vertex AI. Leach said the food logging comes through the same technology used in the base engines for the Stelo CGM’s insight report.
This marks the introduction into the G7 platform for the technology, which right now captures the meal and its description. Down the line, Leach said it could get to the point where it presents macros like carbohydrates.
Read more about Dexcom’s type 2 diabetes report.
Read more from Leach on AI, partnerships and type 2.
A new all-in-one pump from PharmaSens and SiBionics could be on the way
In the case of PharmaSens and SiBionics, all-in-one really means all-in-one. Combining pump and CGM into one device, the companies hope to bring a differentiated offering to the diabetes community.
Last week, the two companies announced plans to develop the next-generation Niia Signature insulin patch pump. The all-in-one wearable device would integrate insulin delivery from Switzerland-based PharmaSens and glucose sensing from China-based SiBionics into a single, compact automated patch pump system.
Speaking to Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, PharmaSens CEO Marcel Both and SiBionics Chief Strategy Officer Patrick Nowlin explained the aim of the two companies in providing this new technology to the diabetes community.
Read more from the PharmaSens and SiBionics officials.
Sequel Med Tech reveals launch for twiist
Sequel built its twiist system on underlying drug delivery technology developed by DEKA R&D. Dean Kamen, co-founder of Sequel and founder of DEKA, commercialized the first wearable insulin pump for diabetes and last year said the twiist system “represents the next generation of insulin delivery.” Sequel won FDA clearance for the twiist system in March 2024.
Combined with the twiist Loop algorithm, the pump directly measures the volume of insulin delivered with every microdose. It offers the capability and flexibility to address each patient’s individual dosing needs. Sequel’s system utilizes sound waves that measure each pulse of insulin. This enables precision and helps understand exactly how much insulin the patient receives in a dose.
Sequel’s launch will come with the Abbott FreeStyle Libre 3 Plus system. The company also has a deal to integrate the pump with the Senseonics Eversense 365 year-long implantable CGM.
Read more about the Sequel Med Tech twiist launch.
Beta Bionics unveils insulin patch pump system
Company officials at Beta Bionics (Nasdaq:BBNX) revealed plans to analysts at ADA, outlining a new insulin patch pump system launch in the U.S. by the end of 2027.
BTIG’s Marie Thibault, Sam Eiber and Alexandra Pang said the company revealed the new Mint system in a live demonstration at the American Diabetes Association’s 85th Scientific Sessions, outlining its plan for an eventual launch within the next couple of years.
According to the analysts, the company plans to offer Mint exclusively through the pharmacy channel. Intended for a three-day use, it would feature a 12-hour grace period.
“We were impressed by the form factor of the patch pump and its ease of use,” the analysts said. “The company continues to anticipate a commercial launch by the end of 2027 upon FDA 510(k) approval. Beta Bionics intends to build up their manufacturing capacity for Mint ahead of a broad-based commercial launch.”
Read more about another potential competitor on the patch pump market.
Next-gen automation on the way at Insulet
“We’re really happy with our product adoption,” Ly said. “You can see by our growth. It’s a very simple and easy-to-use product, and it reaches a lot more patients than other products on the market.”
The latest updates at the company include a continued rollout for the type 2 diabetes population and a new iPhone app. The app, in particular, garnered attention as Ly said it’s been a request from customers for as long as she’s been at the company. It launched the Omnipod 5 App for iPhone with Dexcom’s G7.
The app offers full control of Omnipod 5, including the ability to bolus, change a pod, adjust settings, access insights and more. Users can now download the new app with Dexcom G7 and G6 compatibility from the Apple App Store.
Insulet also has a new data management platform for Omnipod and plans to bring new automation algorithms to clinical trials.
Read more from Ly on new milestones and things to look forward to at Insulet.
Glucotrack’s 3-year implant represents a new way to monitor glucose
Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely.
Chief Scientific Officer Mark Tapsak gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of ADA’s “Innovation Hub,” outlining a potentially difference-making technology.
Earlier this year, the company completed the first-in-human study of the system. It shared findings from that study, which met all endpoints, at ADA.
Now, it expects FDA investigational device exemption (IDE) in the fourth quarter of 2025. The study would likely help the company work toward a submission to bring the device to market in the U.S. down the line.
Glucotrack’s device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, less intrusive solution.
Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the blood. It aims to provide real-time readings without the lag time typically associated with interstitial glucose measurements.
Read more from Tapsak on Glucotrack’s innovative long-term implant.
Read about the results from the company’s first-in-human study.
Next-gen systems are on the way at Senseonics
Senseonics (NYSE:SENS) hosted an analyst event at ADA, sharing updates on its existing Eversense 365 platform and upcoming sensors.
Funds also support the product pipeline, the company says. It anticipates the proceeds to help its cash runway extend through the development and commercialization of next-generation platforms in fiscal 2027.
Senseonics has its Gemini system on track to begin an FDA investigational device exemption study later this year. It aims to launch that system by the fourth quarter of 2026. Freedom remains in prototype testing, with a functional system earmarked for the fourth quarter of this year. Senseonics targets a pivotal study in the fourth quarter of 2026 and a commercial launch in the fourth quarter of 2027.
Read more about the next-generation sensors under development at Senseonics.
MannKind hopes to bring inhaled insulin to more people with diabetes
Founded in 1991 by Alfred E. Mann, a medtech visionary who played a large part in the wider adoption of insulin pumps as the founder of MiniMed, the company develops Afrezza — a fast-acting insulin formulation delivered through an inhaler device.
Speaking with Drug Delivery Business News at the American Diabetes Association’s 85th Scientific Sessions in Chicago, MannKind Director of Medical and Scientific Engagement Joanne Rinker, MS, RDN, BC-ADM, CDCES, LDN, FADCES, explained the benefits of the inhaled insulin technology.
The company also shared new study results at ADA that demonstrated the safety and efficacy of Afrezza for children with type 1 diabetes. Data showed that inhaled insulin offers a safe and effective replacement for rapid-acting meal insulin in children with type 1.
Read more about the Afrezza data.
Read more from Rinker on how MannKind offers people with diabetes another option.
Other highlights from the American Diabetes Association’s 85th Scientific Sessions
- Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy
- Vaxess study highlights GLP-1 delivery with microarray patch
- LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
- Modular Medical study shows potential benefits of pump-delivered GLP-1s
- Lilly to submit once-weekly insulin for regulatory review this year following strong clinical results
- Endogenex data supports type 2 diabetes procedure
